Focused on kinase inhibitors for treatments for Bowel, Eye and Lung diseases
Amakem's partnered kinase platform is based on its ‘Localized Drug Action' platform that generates novel kinase inhibitors that target a reduction in inflammation and fibrosis formation combined with a minimum systemic exposure with the aim to reduce side effects.
- CEO Mr. Jack Elands
- Industry Biotech
- History Other